Visual field loss in young children and mentally handicapped adolescents receiving vigabatrin

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 7, 2006, Pages 3028-3035

  Werth, Reinhard ^a   Schädler, Gereon ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b Kinderzentrum Munchen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ORPHIRIL; PHENYTOIN; PIRIMIDON; SULTIAME; VALPROIC ACID; VIGABATRIN;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FOCAL EPILEPSY; GRAND MAL SEIZURE; HUMAN; INFANTILE SPASM; LENNOX GASTAUT SYNDROME; MALE; MENTAL DEFICIENCY; PRIORITY JOURNAL; TEMPORAL LOBE EPILEPSY; TREATMENT DURATION; VISUAL FIELD; VISUAL FIELD DEFECT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EPILEPSY; HANDICAPPED CHILD; INFANT; MENTAL PATIENT; METHODOLOGY; PERIMETRY; PRESCHOOL CHILD; VISUAL DISORDER;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DISABLED CHILDREN; EPILEPSY; FEMALE; HUMANS; INFANT; MALE; MENTALLY DISABLED PERSONS; PERIMETRY; VIGABATRIN; VISION DISORDERS; VISUAL FIELDS;

EID: 33746774869     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-0778     Document Type: Article

References (49)

1. Arndt CF, Derambure P, Defoort-Dhellemmes S, Hache JC. Outer retinal dysfunction in patients treated with vigabatrin. Neurology. 1999;52:1201-1205.
2. Ascaso FJ, Lopez MJ, Mauri JA, Cristobal JA. Visual field defects in pediatric patients on vigabatrin monotherapy. Doc Ophthalmol. 2003;107:127-130.
3. Backstrom JT, Hinkle R, Flicker MR. Severe persistent visual field constriction associated with vigabatrin: manufacturers have started several studies (Letter). BMJ. 1997;314:1694-1695.
4. Banin E, Shalev RS, Obolensky A, Neis R, Chowers I, Gross-Tsur V. Retinal function abnormalities in patients treated with vigabatrin. Arch Ophthalmol. 2003;121:811-816.
5. Baulac M, Nordmann JP, Lanoe Y. Severe visual field constriction and side-effects of GABA-mimetic antiepileptic agents. Lancet. 1998;252:546.
6. Besch D, Kurtenbach A, Apfelstedt-Sylla E, et al. Visual field constriction and electrophysiological changes associated with vigabatrin. Doc Ophthalmol. 2002;104:151-170.
7. Blackwell N, Hayllar J, Kelly G. Severe visual field constriction associated with vigabatrin: patients taking vigabatrin should have regular visual field testing (Letter). BMJ. 1997;314:1694.
8. Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, Zackon D. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology. 1999;106:1792-1798.
9. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ. 1997;314:180-181.
10. Frisén L. Vigabatrin associated loss of vision: rarebit perimetry illuminates the dose-damage relationship. Acta Ophthalmol Scand. 2004;82:54 -58.
11. Gross-Tsur V, Banin E, Shahar E, Shalev RS, Lahat E. Visual impairment in children with epilepsy treated with vigabatrin. Ann Neurol. 2000;48:60-64.
12. Harding GF. Severe persistent visual field constriction associated with vigabatrin: four possible explanations exist (Letter). BMJ. 1997;314:1694.
13. Hardus P, Verduin WM, Engelsman M, et al. Visual field loss associated with vigabatrin: quantification and relation to dosage. Epilepsia. 2001;42:262-267.
14. Hardus P, Verduin WM, Berendschot TT, et al. The value of electrophysiological results in patients with epilepsy and vigabatrin associated visual field loss. Acta Ophthalmol Scand. 2001;79:169-174.
15. Iannetti P, Spalice A, Perla FM, Conicella E, Raucci U, Bizzarri B. Visual field constriction in children with epilepsy on vigabatrin treatment. Pediatrics. 2000;106:838-842.
16. Jensen H, Sjo O, Uldall P, Gram L. Vigabatrin and retinal changes. Doc Ophthalmol. 2002;104:171-180.
17. Kälviäinen R, Nousiainen I, Mäntyjärvi M, et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology. 1999;53:922-926.
18. Krakow K, Polizzi G, Riordan-Eva P, Holder G, MacLeod WN, Fish DR. Recovery of visual field constriction following discontinuation of vigabatrin. Seizure. 2000;9:287-290.
19. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology. 1998;50:614-618.
20. Lawden MC, Eke T, Degg C, Harding GFA, Wild JM. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry. 1999;67:716-722.
21. Luchetti A, Amadi A, Gobbi G. Visual field defects associated with vigabatrin monotherapy in children. J Neurol Neurosurg Psychiatry. 2000;69:566.
22. Mackenzie R, Klistorner A. Asymptomatic as well as symptomatic defects occur with vigabatrin (Letter). BMJ. 1998;316:233.
23. Malmgren K, Ben Menachem E, Frisen L. Vigabatrin visual toxicity: evolution and dose dependence. Epilepsia. 2001;42:609-615.
24. Manuchehri K, Goodman S, Siviter L, Nightingale S. A controlled study of vigabatrin and visual abnormalities. Br J Ophthalmol. 2000;84:499-505.
25. McDonagh J, Stephen LJ, Dolan FM, et al. Peripheral retinal dysfunction in patients taking vigabatrin. Neurology. 2003;61:1690-1694.
26. Miller NR, Johnson MA, Paul SR, et al. Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology. 1999;53:2082-2087.
27. Ponjavic V, Andreasson S. Multifocal ERG and full-field ERG in patients on long term vigabatrin medication. Doc Ophthalmol. 2001;102:63-72.
28. Russell-Eggitt IM, Mackey DA, Taylor DS, Timms C, Walker JW. Vigabatrin associated visual field defects in children. Eye. 2000;14:334-339.
29. Schmitz B, Schmidt T, Jokiel B, Pfeiffer S, Tiel-Wilk K, Ruther K. Visual field constriction in epilepsy patients with vigabatrin and other antiepileptic drugs: a prospective study. J Neurol. 2002;249:469-475.
30. Spencer EL, Harding GF. Examining visual field defects in the paediatric population exposed to vigabatrin. Doc Ophthalmol. 2003;107:281-287.
31. Toggweiler S, Wieser HG. Concentric visual field constriction under vigabatrin therapy: extend depends on the duration of drug intake. Seizure. 2001;10:420-423.
32. van der Torren K, Grandiewski-Wijnands HS, Polak BC. Visual field and electrophysiological abnormalities due to vigabatrin. Doc Ophthalmol. 2002;104:181-188.
33. Vanhatalo S, Pääkkönen L. Visual field constriction treated with vigabatrin. Neurology. 1999;52:1713-1714.
34. Vanhatalo S, Alen R, Riikonen R, et al. Reversed visual field constriction in children after vigabatrin withdrawal: true recovery or improved test performance only? Seizure. 2001;10:508-511.
35. Versino M, Veggiotti P. Reversibility of vigabatrin: induced visual field defect. Lancet. 1999;354:486.
36. Wilson EA, Brodie MJ. Severe persistent visual field constriction associated with vigabatrin: chronic refractory epilepsy may have role in causing the unusual lesions (Letter). BMJ. 1997;314:1693.
37. Wohlrab G, Boltshauser E, Schmitt B, Schriever S, Landau K. Visual field constriction is not limited to children treated with vigabatrin. Neuropediatrics. 1999;30:130-132.
38. Wong ICO, Mawer GE, Sander J W. Severe persistent visual field constriction associated with vigabatrin: reaction may be dose dependent (Letter). BMJ. 1997;314:1693-1694.
39. Aulhorn E, Harms H. Visual perimetry. In: Jameson D, Hurvich LM, eds. Visual Psychophysics. Berlin: Springer Verlag; 1972:102-145.
40. Küchle HJ, Busse H. Augenerkrankungen im Kindesalter. Stuttgart, Germany: Thieme; 1985.
41. Lewis TL, Maurer D. The development of the temporal and nasal visual fields during infancy. Vision Res. 1992;32:903-911.
42. Mayer DL, Fulton AB, Cummings MF. Visual fields of infants assessed with a new perimetric technique. Invest Ophthalmol Vis Sci. 1988;29:452-459.
43. Werth R, Moehrenschlager M. The development of visual functions in cerebrally blind children during a systematic visual field training. Rest Neurol Neurosci. 1999;15:229-241.
44. Werth R, Seelos K. Restitution of visual functions in cerebrally blind children. Neuropsychologia. 2005;43:2011-2023.
45. Tewes U. Der Hamburg-Wechsler-Intelligenztest für Kinder (HAWIK-R). Bern, Switzerland: Huber; 1983.
46. Ackermann H. BiAS. Biometrische Analysen von Stichproben. Hochheim, Darmstadt, Germany: Epsilon-Verlag; 2005.
47. Best JL, Acheson JF. The natural history of vigabatrin associated visual field defects in patients eliciting to continue their medication. Eye. 2005;19:41-44.
48. Fledelius HC. Vigabatrin-associated visual field constriction in a longitudinal series: reversibility suggested after drug withdrawal. Acta Ophthalmol Scand. 2003;81:41-46.
49. Hardus P, Verduin WM, Berendschot T, Postma G, Stilma JS, van Veelen CW. Vigabatrin: longterm follow-up of electrophysiology and visual field examination. Acta Ophthalmol Scand. 2003;81:459-465.